Lupin Pharmaceuticals Inc. recalls Liraglutide Injection
- Recalling company
- Lupin Pharmaceuticals Inc.
- Product
- Liraglutide Injection, 18 mg/3 mL (6 mg/mL), Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Naples, FL 34108, Manufactured by: Lupin Limited, Nagpur 441108, INDIA, a) 2 Pens- NDC 70748-346-02; b) 3 Pens - NDC 70748-346-03.
- Reason
- Presence of particulate matter: a white thread-like structure in the cartridge
- Classification
- Class II – may cause temporary or medically reversible health consequences
- Recall date
- Apr 24, 2026
- Reported
- May 27, 2026
- Distribution
- Nationwide within U.S
- Status
- Ongoing
- Quantity
- 217,621 pen injectors
- Lot / codes
- Lots: a) WB00097, WB00094, WB00088, Expires: Jul. 2027; WB00103, Expires: Oct. 2027; WC00016, Expires: Dec. 2027; b) WB00098, WB00092, WB00093, Expires: Jul. 2027; WB00104, WB00106, WB00105, Expires: Oct. 2027.
- Company location
- Naples, FL
- Recall type
- Voluntary: Firm initiated
- Recall number
- D-0541-2026
- Agency
- U.S. Food and Drug Administration (FDA)
View official FDA notice ↗ Search recall number D-0541-2026 in the FDA Enforcement Report. Also see FDA recall press releases.
If you use this product, check the lot, NDC or model number against the official notice and follow its instructions. Do not stop a prescribed medicine or remove a medical device without talking to your doctor or pharmacist. Report problems to FDA MedWatch. FoodRecallNow summarizes public FDA data and is not medical advice.